All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
![General Image 1 General Image 1](https://assets.mrmed.in/product-images/General+New.jpg)
![General Image 2 General Image 2](https://assets.mrmed.in/product-images/General+New+2.jpg)
![General Image 1 General Image 1](https://assets.mrmed.in/product-images/General+New.jpg)
Livonibe 200mg Tablet 30's
Prescription Required
Salt Composition : Sorafenib
Manufacturer : BDR PHARMACEUTICALS INTERNATIONALS PVT LTD
Origin of Medicine : India
30 Tablet(s) In A Bottle
Introduction to Livonibe 200mg Tablet 30's
Livonibe 200mg tablet 30's belongs to the group of medicines called anti-cancer. It consists of the active ingredient Sorafenib that is indicated for advanced renal cell carcinoma (kidney cancer), advanced hepatocellular carcinoma (liver cancer) in patients ineligible for surgery and differentiated thyroid carcinoma (thyroid cancer) in patients who are not responsive to radioactive iodine therapy.
Diarrhea, tiredness, stomach pain, nausea, weakness, rashes, flu-like illness, appetite loss, nausea, weight loss, and low blood calcium levels are common side effects of livonibe 200mg tablet 30's. Inform your doctor if any of these side effects disturbs or persists you.
Inform your doctor if you are allergic to livonibe 200mg tablet 30's and its ingredients. Before starting treatment with livonibe 200mg tablet 30's, you should let your physician know if you have heart problems, chest pain, bleeding problems, high blood pressure, or have had or are about to have surgery. Use effective contraception during the therapy and for 6 months after the last dose if you are a woman or 3 months after the last dose if you are a man.
Uses of Livonibe 200mg Tablet 30's
Livonibe 200mg tablet 30's is used to treat:
- Advanced renal cell carcinoma
- Advanced hepatocellular carcinoma that cannot be surgically treated
- Advanced papillary and follicular Hurtle cell thyroid carcinoma
Therapeutic Effects of Livonibe 200mg Tablet 30's
Livonibe 200mg tablet 30's is a small molecule that works by inhibiting multiple receptor tyrosine kinases (enzymes), primarily vascular endothelial growth factor receptors and platelet-derived growth factor-β receptors. This prevents the development of blood vessels in tumor cells (angiogenesis) and arrests the growth and spread of the tumor cells to other organs.
Interaction of Livonibe 200mg Tablet 30's with other drugs
Inform your doctor about any medications you are taking or have taken before the treatment.
More Information about Livonibe 200mg Tablet 30's
Store below 30°C in a dry place.
How to consume Livonibe 200mg Tablet 30's
Take the tablet without food (1 hour before or 2 hours after meal). Swallow with a glass of water.
Safety Advices for Livonibe 200mg Tablet 30's
Pregnancy
It is unsafe to use livonibe 200mg tablet 30's during pregnancy as it may harm the unborn baby. Inform your physician before starting this treatment if you are pregnant or think you might be pregnant. Your physician will conduct a pregnancy test before prescribing this medicine for you.
Breast Feeding
Do not breastfeed during treatment with livonibe 200mg tablet 30's and for two weeks after the last dose. It is vital to let your physician know if you are breastfeeding or planning to breastfeed before starting treatment with this drug.
Lungs
Liver
Individuals with liver disease should consult a healthcare provider, especially those with liver conditions.
Alcohol
Avoid consuming alcohol with livonibe 200mg tablet 30's as it may cause unpleasant side effects.
Driving
This medicine could cause peripheral sensory neuropathy that causes an impact on driving. Hence, avoid driving or doing things that require focus during this treatment period.
Side Effects of Livonibe 200mg Tablet 30's
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Serious:
- Stevens Johnsons Syndrome and toxic epidermal necrosis
- Decreased blood flow to the heart
- Increased risk of bleeding (blood in urine, stool, vomit, cough, etc)
- High BP
- Skin problems
- Liver problems
- Problems in wound healing
Common:
- Nausea, stomach pain, diarrhea
- Tiredness and weakness
- Infection
- Hair thinning and patchy hair loss
- Rash
- Weight loss
- Loss of appetite
- Low levels of calcium in the blood
- Flu-like illness
Word of Advice
It is advised to seek immediate medical attention if your face swelling in your lower legs, or fast heartbeats, trouble breathing. It may be a sign of a heart problems. It may result in bleeding hence inform your doctor if you see blood in stools or urine.
FAQs
Q 1. Can diabetic person take livonibe 200mg tablet 30's?
Yes, livonibe 200mg tablet 30's is safe to be taken by diabetic individual. However, only take after seeing a doctor, as they may change the dose based on the patient's condition.
Q 2. What are the conditions in which livonibe 200mg tablet 30's use is prohibited?
Livonibe 200mg tablet 30's is not recommended for people who are allergic to any of its ingredients, have squamous cell lung cancer, or are already taking carboplatin and paclitaxel.
Q 3. When should I stop taking livonibe 200mg tablet 30's as a treatment?
Livonibe 200mg tablet 30's should be discontinued if a person experiences a major adverse effect that impairs their quality of life. If not, you must continue taking this medication until your physician instructs you to stop.
Q 4. What class of medication is livonibe 200mg tablet 30's?
Livonibe 200mg tablet 30's belongs to the group of medicines called anti tumor and tyrosine kinase inhibitors.
Q 5. Can I use alcohol while taking livonibe 200mg tablet 30's?
Livonibe 200mg tablet 30's is not to be taken with alcohol as it may cause unpleasent side effects.
Fact Box of Livonibe 200mg Tablet 30's
Molecule name: Sorafenib | Therapeutic Class : Tyrosine kinase inhibitors |
Pharmacological class: Antineoplastics | Indication:
|
References
- Bayer (Pty) Ltd, [Revised on 22nd Apr 2016] [Accessed on 22 Nov 2022], https://www.bayer.com/sites/default/files/NEXAVAR_200_EN_PI.pdf
- Bayer HealthCare Pharmaceuticals Inc., US Food & Drug Administration, [Revised on Dec 2018] [Accessed on 22 Nov 2022]], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021923s020lbl.pdf
- Ciplamed, [Revised on Dec 2017] [Accessed on 22 Nov 2022]], https://www.ciplamed.com/print-product-pdf/24207
- Edward Chu, Cancer Chemotherapy, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 948-976.
- KD Tripathi, Anticancer Drugs, Essentials of Medical Pharmacology, 8th Edition, 2019, 915-936.
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.